# IMCIVREE® (setmelanotide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/setmelanotide

> The FDA approved IMCIVREE® (setmelanotide), sponsored by RHYTHM PHARMACEUTICALS, INC. (RYTM), on March 19, 2026 for acquired HO.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is IMCIVREE® (setmelanotide) FDA approved?

Yes. The FDA approved IMCIVREE® (setmelanotide), sponsored by RHYTHM PHARMACEUTICALS, INC. (RYTM), on March 19, 2026 for acquired HO. Press release filed with the SEC (EX-99): "•On March 19, 2026, the Company announced IMCIVREE was approved by the FDA for the treatment of acquired HO;" [Calendar and source filings](https://sec-api.dev/pdufa/setmelanotide)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-030136, https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/q12026earningspr_draft.htm (retrieved 2026-11-12). Last confirmed 2026-05-05. Cite: https://sec-api.dev/pdufa/setmelanotide#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | IMCIVREE® (setmelanotide) |
| Codes | RM-493 |
| Sponsor | RHYTHM PHARMACEUTICALS, INC. (RYTM) https://sec-api.dev/companies/rytm/catalysts |
| Indications | [acquired hypothalamic obesity](https://sec-api.dev/indications/acquired-hypothalamic-obesity), acquired ho, living with acquired hypothalamic obesity, conditions associated with hypothalamic obesity, conditions associated with acquired hypothalamic obesity, [acquired hypothalamic obesity -](https://sec-api.dev/indications/acquired-hypothalamic-obesity), [Hypothalamic Obesity](https://sec-api.dev/indications/hypothalamic-obesity), [Obesity](https://sec-api.dev/indications/obesity) |
| Modality | peptide |
| FDA designations | breakthrough, priority review |

## Timeline

### November 25, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213793 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20201125, review_priority PRIORITY; sponsor_name RHYTHM; product IMCIVREE (SETMELANOTIDE ACETATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213793%22

### Jun 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-01-10, last confirmed 2025-01-10.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000093): "FDA approved IMCIVREE for BBS in June 2022" https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d2.htm

### June 16, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213793 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220616, review_priority PRIORITY; sponsor_name RHYTHM; product IMCIVREE (SETMELANOTIDE ACETATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213793%22

### December 20, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-26, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213793 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority PRIORITY; sponsor_name RHYTHM; product IMCIVREE (SETMELANOTIDE ACETATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213793%22
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001553): "On December 20, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for IMCIVREE to include children as young as 2 years old with syndromic or monogenic obesity due to BBS or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency;" https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226xex99d1.htm

### Q1 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-01-10, last confirmed 2025-01-10.
- SEC Form 8-K (accession 0001558370-25-000093): "The Company plans to initiate a new, 26-week, open-label Phase 2 trial evaluating setmelanotide for treatment of Prader-Willi Syndrom ("PWS") in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000093): "Today, Rhythm announced it plans to initiate a new, 26-week, open-label Phase 2 trial evaluating setmelanotide for treatment of PWS in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d1.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Indication: acquired hypothalamic obesity -.
- First seen 2025-01-10, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-003374): ""Our global trial of setmelanotide in patients with acquired hypothalamic obesity - which is on track for topline data readout in the second quarter of 2025 - is being conducted in North America, Europe and Japan, and this reacquisition of rights for China, Hong Kong and Macau means Rhythm now owns the global franchise." https://www.sec.gov/Archives/edgar/data/1649904/000155837025003374/rytm-20250314xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-001889): "We are on track to report top-line study results in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001889): "We expect to report top-line study results in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000093): "On track to report topline data from pivotal, Ph3 trial in acquired hypothalamic obesity in H1 25" https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d2.htm

### April 7, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: acquired hypothalamic obesity.
- First seen 2025-01-10, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004507): "BOSTON, April 7, 2025 - Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity." https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-106264): "On April 7, 2025, we announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity." https://www.sec.gov/Archives/edgar/data/1649904/000110465925106264/rytm-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010302): "On April 7, 2025, we announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity." https://www.sec.gov/Archives/edgar/data/1649904/000155837025010302/rytm-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006765): "On April 7, 2025, we announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity." https://www.sec.gov/Archives/edgar/data/1649904/000155837025006765/rytm-20250331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001553): "-- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 --" https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226xex99d1.htm
- SEC Form 8-K (accession 0001558370-25-000093): "The Company is on track to report topline data from its Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity (the "Phase 3 acquired HO trial") in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000093): "-- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 --" https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000093): "The Company is on track to report topline data from the pivotal, 120-patient cohorts of its global, Phase 3 trial evaluating setmelanotide in acquired HO in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-001889): "Prepare for potential global launch of IMCIVREE in hypothalamic obesity: With topline data in our Phase 3 pivotal trial on track to be disclosed in the second quarter of 2025, we are focused on efficiently analyzing that data, and submitting regulatory filings in the United States, the EU and the United Kingdom - to be followed by a regulatory submission in Japan - and preparing for global commercialization, if approved." https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001889): "We are on track and plan to read out topline data from our ongoing Phase 3 clinical trial evaluating setmelanotide as a treatment for acquired hypothalamic obesity in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001553): ""Our Phase 3 trial in acquired hypothalamic obesity (HO) remains on track as we expect to disclose topline data in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-001889): "We have completed enrollment in our Phase 3 trial in patients with acquired hypothalamic obesity and we are on track to disclose topline data in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm

### April 7, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-05-07, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-006602): "On April 7, 2025, Rhythm announced it dosed the first patients with Prader-Willi syndrome in a 26-week, open-label Phase 2 trial of setmelanotide." https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507xex99d1.htm
- SEC Form 10-Q (accession 0001558370-25-006765): "Additionally, on April 7, 2025, we announced that we dosed the first patients with Prader-Willi syndrome in a 26-week, open-label Phase 2 trial of setmelanotide." https://www.sec.gov/Archives/edgar/data/1649904/000155837025006765/rytm-20250331x10q.htm

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-05-07, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-006602): ""Following compelling topline results from our pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity (HO), we look forward to completing U.S. and EU regulatory submissions in the third quarter of 2025 and, pending approval, bringing the first-ever known approved therapy for this serious disease to patients," said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm." https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507xex99d1.htm

### August 20, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: conditions associated with acquired hypothalamic obesity.
- First seen 2025-11-04, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105904): "On August 20, 2025, Rhythm announced that the U.S. Food and Drug Administration (FDA) accepted for filing the Company's sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity." https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-106264): "On August 20, 2025, we announced that the U.S. FDA accepted for filing our supplemental New Drug Application (sNDA) for setmelanotide seeking approval for the treatment of conditions associated with hypothalamic obesity." https://www.sec.gov/Archives/edgar/data/1649904/000110465925106264/rytm-20250930x10q.htm

### December 11, 2025: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2026-05-05, last confirmed 2026-05-05.
- SEC Form 10-Q (accession 0001628280-26-030549): "On December 11, 2025, we announced positive interim results from our exploratory Phase 2 trial of setmelanotide in patients with PWS." https://www.sec.gov/Archives/edgar/data/1649904/000162828026030549/rytm-20260331.htm

### December 19, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obesity; Genetic Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05093634 (EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-11-12." https://clinicaltrials.gov/study/NCT05093634

### December 20, 2025: PDUFA date

- Status: delayed. Date confidence: exact.
- First seen 2025-11-04, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105904): "-- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity --" https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105904): "Receive a decision from the FDA on our sNDA (anticipated to be received by the PDUFA goal date of December 20, 2025) for setmelanotide in conditions associated with acquired hypothalamic obesity;" https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-106264): "Receive a decision from the FDA on our sNDA (anticipated to be received by the PDUFA goal date of December 20, 2025) for setmelanotide in conditions associated with acquired hypothalamic obesity;" https://www.sec.gov/Archives/edgar/data/1649904/000110465925106264/rytm-20250930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105904): "The FDA granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2025." https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-106264): "The FDA granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2025." https://www.sec.gov/Archives/edgar/data/1649904/000110465925106264/rytm-20250930x10q.htm
- SEC Form 10-K (accession 0001628280-26-012399): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 20, 2026, an extension from the original assigned goal date of December 20, 2025." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm

### January 9, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-01-09, last confirmed 2026-01-09.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-001459): "® 4 Continued Growth in IMCIVREE Global Sales ~10% increase in number of patients globally on reimbursed therapy 11% Q4 2025 preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) QoQ increase from Q3 2025** 68% of Q4 2025 revenue from U.S. 69% of FY 2025 revenue from U.S. $57M* Q4 2025 ~ $194M FY 2025 ~ The Company plans to report fourth quarter and full year 2025 financial results in February * Preliminary, unaudited Q4 2025 revenue from vials shipped to U.S. specialty pharma in excess of vials dispensed to patients is approximately $1.7M; **Reminder: During Q3 2025, Rhythm recorded a one-time $3.2 million charge following a final agreement with French authorities for reimbursement for IMCIVREE for POMC/LEPR and BBS." https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/exhibit992rytm_january20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-001459): "The Company plans to report its fourth quarter and full year 2025 financial results in late February 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/exhibit991rytmq42025prel.htm

### Mar 2026: topline data readout

- Status: scheduled. Date confidence: month. Stage: 3. Indication: acquired hypothalamic obesity.
- First seen 2025-01-10, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004507): "A supplemental cohort of 12 Japanese patients remains ongoing with completion and topline data anticipated in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000093): "Enrollment completed in 4Q 2024; Topline data anticipated in H1 2026" https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d2.htm
- SEC Form 10-K (accession 0001628280-26-012399): "We anticipate reading out topline data from this trial in March 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm
- SEC Form 10-K (accession 0001628280-26-012399): "We anticipate reporting topline data in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm
- SEC Form 10-K (accession 0001558370-25-001889): "We anticipate reporting topline data in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011987): "-- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 --" https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011987): "-- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 --" https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-001459): "Anticipated Upcoming Milestones Setmelanotide Acquired Hypothalamic Obesity (HO)  Launch IMCIVREE in the United States for the treatment of acquired hypothalamic obesity pending FDA approval; the FDA's assigned PDUFA goal date is March 20, 2026;  Announce topline data in the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired HO in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/exhibit991rytmq42025prel.htm
- SEC Form 10-K (accession 0001628280-26-012399): "We anticipate disclosing topline data from a 12-patient Japanese cohort of our Phase 3 trial evaluating setmelanotide for acquired hypothalamic obesity in March 2026, and pending positive data, completing a new drug application submission in Japan." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm
- SEC Form 10-K (accession 0001628280-26-012399): "Our Phase 3 EMANATE trial, comprised of four independent substudies evaluating setmelanotide in genetically caused MC4R pathway diseases, is ongoing with topline data expected in March 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm
- SEC Form 8-K (accession 0001558370-25-000093): "The Company anticipates reporting topline data from the Phase 3 EMANATE trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110x8k.htm

### March 19, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: acquired HO.
- First seen 2026-03-20, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-030136): "•On March 19, 2026, the Company announced IMCIVREE was approved by the FDA for the treatment of acquired HO;" https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/q12026earningspr_draft.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-019995): "Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity" https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/ex991hopdufapressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-019995): "Rhythm will host a live conference call and webcast at 5:00 p.m. ET today to discuss the FDA approval of IMCIVREE for patients with acquired HO." https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/ex991hopdufapressrelease.htm

### March 19, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: living with acquired hypothalamic obesity.
- First seen 2026-03-20, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213793 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260319, review_priority PRIORITY; sponsor_name RHYTHM; product IMCIVREE (SETMELANOTIDE ACETATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213793%22
- SEC Form 8-K (accession 0001628280-26-019995): "On March 19, 2026, Rhythm Pharmaceuticals, Inc. ("Rhythm") issued a press release and published a presentation announcing that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO), which is summarized under Item 8.01 below." https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/rytm-20260319.htm
- SEC Form 8-K (accession 0001628280-26-019995): "On March 19, 2026, Rhythm announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO)." https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/rytm-20260319.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-019995): "BOSTON, March 19, 2026 - Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO)." https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/ex991hopdufapressrelease.htm

### March 20, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Stage: 3. Indication: acquired hypothalamic obesity.
- First seen 2025-11-07, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-021801): "-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --" https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011987): "-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) --" https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011987): "•Launch IMCIVREE in the United States for the treatment of acquired HO pending FDA approval; the FDA's assigned PDUFA goal date is March 20, 2026;" https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011987): "our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates, including the March 20, 2026 PDUFA goal date for our sNDA for setmelanotide in acquired hypothalamic obesity" https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm
- SEC Form 8-K (accession 0001628280-26-001459): "•Launch IMCIVREE in the United States for the treatment of acquired hypothalamic obesity pending FDA approval; the FDA's assigned PDUFA goal date is March 20, 2026;" https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/rytm-20260109.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-001459): "Anticipated Upcoming Milestones Setmelanotide Acquired Hypothalamic Obesity (HO)  Launch IMCIVREE in the United States for the treatment of acquired hypothalamic obesity pending FDA approval; the FDA's assigned PDUFA goal date is March 20, 2026;  Announce topline data in the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired HO in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/exhibit991rytmq42025prel.htm
- SEC Form 10-K (accession 0001628280-26-012399): "Reviews of our regulatory submissions seeking approval and marketing authorization for setmelanotide as a treatment for acquired hypothalamic obesity are ongoing in the United States and Europe, with an FDA-assigned Prescription Drug User Fee Act (PDUFA) goal date of March 20, 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm
- SEC Form 10-K (accession 0001628280-26-012399): "Pending regulatory approvals, we anticipate launching IMCIVREE for acquired hypothalamic obesity in the United States in 2026, based on our FDA-assigned Prescription Drug User Fee Act (PDUFA) goal date of March 20, 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm
- SEC Form 10-K (accession 0001628280-26-012399): "Reviews of our regulatory submissions seeking approval and marketing authorization for setmelanotide as a treatment for acquired hypothalamic obesity are ongoing in the United States and Europe with an FDA-assigned Prescription Drug User Fee Act (PDUFA) goal date of March 20, 2026." https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-021801): "our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates, including the sNDA to the FDA and the PDUFA goal date of March 20, 2026, including the submission of the final data package to the FDA, the Type II variation request to the EMA and the anticipated decision by the CHMP to issue an opinion to EC and potential marketing authorization in the second half of 2026" https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-108154): "­-- FDA sets updated PDUFA goal date of March 20, 2026 -" https://www.sec.gov/Archives/edgar/data/1649904/000110465925108154/rytm-20251106xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-108154): "On Nov. 6, the FDA notified the Company that the Prescription Drug User Fee Act (PDUFA) goal date has been extended from December 20, 2025 to March 20, 2026." https://www.sec.gov/Archives/edgar/data/1649904/000110465925108154/rytm-20251106xex99d1.htm

### June 24, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obesity Associated With Defects in Leptin-melanocortin Pathway.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06596135 (Open-Label Extension Study of Setmelanotide): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-24 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06596135

### November 3, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Prader-Willi Syndrome; Obesity; Hyperphagia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06772597 (A Study of Setmelanotide in Patients With Prader-Willi Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-03 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06772597

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Prader-Willi Syndrome; Obesity; Hyperphagia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06772597 (A Study of Setmelanotide in Patients With Prader-Willi Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-03 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06772597

### November 12, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obesity; Genetic Obesity.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05093634 (EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-11-12." https://clinicaltrials.gov/study/NCT05093634?tab=results

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06760546 (A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-13 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06760546

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06760546 (A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-13 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06760546

## Same indication

- [ABBV-295](https://sec-api.dev/pdufa/abbv-295) (ABBV)
- [AZD6234](https://sec-api.dev/pdufa/azd6234) (AZN)
- [Berobenatide](https://sec-api.dev/pdufa/berobenatide) (PFE)
- [Bivamelagon](https://sec-api.dev/pdufa/bivamelagon) (RYTM)
- [Cagrilintide](https://sec-api.dev/pdufa/cagrilintide) (NVO)
- [Cagrisema (cagrilintide b and semaglutide i)](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) (NVO)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)
- [Eloralintide](https://sec-api.dev/pdufa/eloralintide) (LLY)
- [KAI-7535](https://sec-api.dev/pdufa/kai-7535) (KLRA)
- [LY3549492](https://sec-api.dev/pdufa/ly3549492) (LLY)
- [LY4086940](https://sec-api.dev/pdufa/ly4086940) (LLY)
- [Macupatide](https://sec-api.dev/pdufa/macupatide) (LLY)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Met097 injection](https://sec-api.dev/pdufa/met097) (PFE)
- [Nimacimab](https://sec-api.dev/pdufa/nimacimab) (SKYE)
- [NNC0487-0111](https://sec-api.dev/pdufa/nnc0487-0111) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [PF-07976016](https://sec-api.dev/pdufa/pf-07976016) (PFE)
- [PF-08653944](https://sec-api.dev/pdufa/pf-08653944) (PFE)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [Ribupatide](https://sec-api.dev/pdufa/ribupatide) (KLRA)
- [RM-718](https://sec-api.dev/pdufa/rm-718) (RYTM)
- [Taldefgrobep alfa](https://sec-api.dev/pdufa/taldefgrobep-alfa) (BHVN)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [NEREUSTM (tradipitant)](https://sec-api.dev/pdufa/tradipitant) (VNDA)
- [Trevogrumab-part a](https://sec-api.dev/pdufa/trevogrumab-part-a) (REGN)
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide) (NVO)

Calendar months: [December 2025](https://sec-api.dev/fda-calendar/2025-12), [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/setmelanotide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMCIVREE® (setmelanotide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/setmelanotide

```bibtex
@misc{secapidev_pdufa_setmelanotide_20261116,
  title        = {IMCIVREE® (setmelanotide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/setmelanotide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_setmelanotide_20261116","title":"IMCIVREE® (setmelanotide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/setmelanotide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
